Broad Spectrum SPF 47, PFA (PPD) ~24 Sunscreen Cream UVA1/UV = 0.82

Hallstar
Phase
Product
INCI Name
Supplier
Volume
A
HallBrite ® OS USP
Ethylhexyl Salicylate [Octisalate]
5.00
HallBrite ® HS USP
Homosalate [Homosalate]
15.00
HallBrite ® BHB
Butyloctyl Salicylate
5.00
Crodamol ™ AB-LQ-(MH)
C12-15 Alkyl Benzoate
5.00
SolaStay ® S1
Ethylhexyl Methoxycrylene
4.00
Neo Heliopan ® 303
Octocrylene [Octocrylene]
2.75
B
Neo Heliopan ® 357
Butyl Methoxydibenzoylmethane [Avobenzone]
3.00
Neo Heliopan ® BB,
Benzophenone-3 [Oxybenzone]
6.00
C
Tego ® Care 450
Polyglyceryl-3 Methylglucose Distearate
3.00
HallStar ® GMS SE/AS
Glyceryl Stearate, PEG-100 Stearate
1.50
Emulsiphos ®
Potassium Cetyl Phosphate, Hydrogenated Palm Glycerides
2.00
D
-
Water [deionized]
43.05
Versene ™ NA
Disodium EDTA
0.05
Rhodicare ® XC
Xanthan Gum
0.15
E
CoSept ™ PEP
Phenoxyethanol, Methylparaben, Ethylparaben, Butylparaben, Propylparaben, Isobutylparaben
0.50
Superol ™ K Glycerine 99.7% USP/FCC Kosher
Glycerin
4.00

Preparation:

In a secondary vessel, combine 1 through 6 and start mixing. Add 7 and 8 and start heating to 80°C. When above 60°C add 9, 10 and then 11. To the main vessel add 12, start mixing, and add 13. When dissolved add 14 and, when fully incorporated, start heating to 80°C and add premix of 15 and 16. With both phases homogeneous and at 80°C, add the oil phase (1-11) to the water phase (12-16) with prop stirring and then homogenize for five minutes. Switch from homogenization to sweep mixing and cool to ambient temperature. Add water as needed to correct for evaporative loss and, when again uniform, perform final quality assurance checks.

Notes:

PRODUCT CHARACTERISTICS (25?C) Appearance: Light yellow cream pH: 6.0 Viscosity (RV, T-D, 5, 20 & 100 rpm, cP): 51600, 16600 & 4700
Disclaimer

While every effort has been made to reproduce these formulations correctly, the Publisher of this website cannot accept any liability for the information presented. All formulations are provided in good faith, but no warranty is given as to accuracy of information or results, or suitability for a particular use, nor is freedom from patent infringement to be inferred. Formulations are offered solely for consideration by the participating manufacturers. Continued use of this web site infers acceptance of this disclaimer.

Latest Issues

Connex-C Asia 2025

Lee Kong Chian School of Medicine - Ong Tiong Tat and Irene Tan Liang Kheng Auditorium 11 Mandalay Road, Level 4, Singapore 308232
31 July - 1 August 2025

IFSCC Congress 2025

Palais des Festivals, Cannes
15th - 18th September 2025